

CURRICULUM VITAE

Dr. Nimer Alkhatib, PharmD, MS, PhD


*Pharmacy/Assistant Professor of Pharmacoeconomics,
Policy, and Health Outcomes*

Al-Zaytoonah University of Jordan, Amman, Jordan

Phone: 00962-6-4291511

Fax: 00962-6-4291432

E-mail: n.alkhatib@zuj.edu.jo



1. Personal Data

Date of Birth: 2 January 1987 (Manhattan, KS, USA)

Nationality: USA and Jordan

2. Education

- Ph.D. (Pharmaceutical economics, policy, and health outcomes) 2019, University of Arizona, Tucson, Arizona, USA
- Certificate (Business Entrepreneurship), 2019 Arizona State University (ASU), Phoenix, Arizona
- M.Sc. (Pharmaceutical economics, policy, and health outcomes) 2017, University of Arizona, Tucson, Arizona, USA
- B.Sc. (PharmD) 2011, Jordan University of Science and Technology, Irbid, Jordan

3. Ph.D. Dissertation

Innovative methods for outcome-based pricing treatments from the US payer perspective (the six delta platform)-University of Arizona, Tucson, USA.

4. Employment

Academic Positions



- Assistant Professor of Pharmacoeconomics, Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
February 23, 2020 – now
- Associate Consultant, Matrix45 Evidence-Based Healthcare, Tucson, USA
April 20, 2020 – Now
- Adjunct Assistant Professor, Pharmacy Practice and Science, University of Arizona, Tucson, USA
February 20, 2020 – Now
- Designated Campus Colleague/ Associate, Center for Health Outcomes and PharmacoEconomic Research (HOPE Center), University of Arizona, USA
March 7, 2020 – Now
- Pre-doctoral fellow, Center for Health Outcomes and PharmacoEconomic Research (HOPE Center), University of Arizona, USA
August 15, 2015, December 30, 2019

Research Positions

- 2020 – present JOURNAL OF HUMAN HYPERTENSION. Reviewer
- 2020 – present JORDAN JOURNAL OF PHARMACEUTICAL SCIENCES. Reviewer
- 2020 – present JOURNAL OF DRUG ASSESSMENT. Reviewer
- 2020 – present JAMA DERMATOLOGY. Reviewer
- 2020 – present JOURNAL OF TAIBAH UNIVERSITY. Reviewer.
- 2017 – present ARIZONA DEPARTMENT OF HEALTH SERVICES FUNDED ECONOMIC PROJECTIONS FOR SMOKING CESSATION PROGRAMS (Phoenix, AZ, USA). Research Group Leader.
- 2017 – present JOURNAL OF CLINICAL THERAPEUTICS (Philadelphia, PA, USA). Editorial Board Consultant.
- 2016 – present CENTER FOR HEALTH OUTCOMES AND PHARMACOECONOMIC RESEARCH (Tucson, AZ, USA). Hematology and Oncology Research Group Leader.
- 2010 – 2011 INTERNATIONAL PHARMACEUTICAL STUDENTS' FEDERATION (IPSF) (Amman, JORDAN). Regional Projects Officer for Eastern Mediterranean Region.
- 2009 – 2010 WORLD HEALTH ORGANIZATION (W.H.O.) (Amman, Jordan). Clinical Data coordinator for a project sponsored by Harvard University on chronic diseases.
- Editorial Board Consultant/ Journal of Clinical Therapeutics (IF= 3), Philadelphia, USA
2017, Now
- Hematology/Oncology Research Group Leader/ Center for Health Outcomes and PharmacoEconomic Research (HOPE), Arizona, USA
2017, 2020



5. Research Interests

- Value-based pricing, Oncology, Biosimilars, Cost-effectiveness, Modelling, Outcome Research.

6. Honors and Awards

- Academic excellence, 2016, University of Arizona, USA
- Academic excellence, 2017, University of Arizona, USA
- Academic excellence, 2018, University of Arizona, USA
- Academic excellence, 2019, University of Arizona, USA

7. Fellowships and Scholarships

- Full scholarship-PhD in Pharmacoeconomics, policy, and health outcome- Sponsored by the University of Arizona, USA 2017-2019
- Partial Scholarship- Certificate of Business Entrepreneurship sponsored by Arizona State University (ASU)
- Full scholarship-Summer School-Genomics and Science of Symptom Management by the University of Basel, Switzerland 2016-2016
- Full scholarship-MS in Pharmacoeconomics, policy, and health outcome- Sponsored by the University of Arizona, USA 2015-2019

9. Teaching Experience

- *Graduate Courses*
 - Health Technology Assessment. College of Pharmacy, University of Arizona, Tucson, USA
 - Applied Health Technology Assessment, College of Pharmacy, University of Arizona, Tucson, USA
- *Undergraduate Courses*
 - Pharmacoeconomics, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
 - Pharmaceutical marketing, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
 - Pharmacy practice (applied), College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
 - Communication skills in pharmacy practice, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan



10. Supervision of Graduate Research

- Mavis Obeng-Kusi: for PhD studies, health technology assessment project 2020-2020
- Evelyn Kim: For senior project-PharmD. University of Arizona 2016-2017
- Yazan Barqawi: For Master's degree in Pharmaceutical Economics. University of New Mexico 2017-2018
- Neda Alrawashdh: For Master's degree in Clinical Translational Sciences. University of Arizona 2018-2020
- Briana Choi: For senior project-PharmD. University of Arizona 2018-2019
- Elizabeth Pae: For senior project-PharmD. University of Arizona 2018-2019
- Kelly Yiu: For senior project-PharmD. University of Arizona 2018-2019

11. Grants

- Principal investigator. Economic evaluation of f Olanzapine, neurokinin-1 receptor antagonist, and thalidomide in combination with palonosetron and dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Umm Al-Qura University, Makkah, Saudi Arabia. Budget: Confidential
- Analyst. Evaluation of smoking cessation clinics and behavior of clients. Department of Family Medicine/ College of Medicine/ University of Arizona. Under Prof. Ivo Abraham. Budget: Confidential
- Analysis group leader "Economic evaluation of smoking cessation vs. persistence for a panel of ~200,000 Arizonans who quit cigarette smoking between 1/1/2011 and 12/31/2015." Arizona Department of Health Services (2017-2018). Direct costs: \$213,450.

12. Professional and Scientific Meetings

Scientific Meetings Organized

- IPSF meeting 2011. Qatar University. Doha. Qatar.
- Clinical Pharmacy Day 2010. Jordan University of Science and Technology. Irbid. Jordan

Participation in Scientific meetings

Abstracts presented and published

1. **Alkhatib N**, Choi B, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS). American Society of Clinical Oncology (ASCO) 2019 USA.
2. Choi B, **Alkhatib N**, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation crizotinib, alectinib and brigatinib in anaplastic



- lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) 2019 USA.
3. Alrawashdh N, **Alkhatib N**, McBride A, Persky D, Abraham I. Economic Evaluation for the US of Ibrutinib versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. American Society of Hematology (ASH) 2018 USA
 4. **Alsaid N**, McBride A, Abraham I. Economic Evaluation for the US of Ibrutinib versus Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Clinical Oncology (ASCO) 2018 USA
 5. Oh M, Almutairi A, **Alsaid N**, Babiker H, McBride A, Abraham I. Progression-Free(PFS) and Overall Survival (OS) in Treatment of BRAF Mutation-Positive Metastatic Melanoma: Bayesian Network Meta-Analysis. American Society of Clinical Oncology (ASCO)2018 USA
 6. **Alsaid N**, McBride A, Oh M, Persky D, Anwer F, Andritsos L, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
 7. **Alsaid N**, McBride A, Kim H, Oh M, Andritsos L, Anwar F, Persky D, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Ibrutinib versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
 8. **Alsaid N**, Sweitzer N, Ramos N, Abraham I. Systematic Review for Causes of Hospitalization in Cost-Effectiveness Studies. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Europe
 9. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Economic Evaluation of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). World Congress of Pharmacy and Pharmaceutical Sciences (FIP) 2017 South Korea
 10. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Cost-Effectiveness of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). American Society of Clinical Oncology (ASCO) 2017 USA
 11. **Alsaid N**, McBride A, Abraham I. Cost-effectiveness of Daratumumab 10mg+Dacarbazine versus Dacarbazine Alone in Metastatic/Advanced Melanoma. Western Pharmacoeconomics Conference 2017 USA
 12. **Alsaid N**, Almutairi A, Fazel M, Lee J, Slack M. Information Required in Research Reports for Inclusion in Meta- analysis: Cohort Studies for Evaluating the Impact of Pharmacist Care on Diabetes Outcomes. American Society of Health-System Pharmacists (ASHP) midyear scientific sessions 2016 USA

13. Presentations and Lectures Invited



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

- **Alkhatib N.** Applied Health Technology. Center for Health Outcomes and PharmacoEconomic Research, Tucson, USA. Spring Semester 2020
- **Alkhatib N.** Feasibility of health care services in Jordan. Jordanian Ministry of Health, Amman, Jordan. Spring 2020
- **Alkhatib N.** Value-Based Pricing of treatments in developed countries. Jordanian Food and Drug Administration. Amman, Jordan. August 2019
- **Alkhatib N.** The Evolving Role of the Oncology Pharmacy: Multidisciplinary Perspectives Pre-Conference (Panel Discussion). Association of Community Cancer Centers, ACCC 35th National Oncology Conference, Phoenix, USA, October 2018
- **Alkhatib N.** Role of Biosimilars in Value-Based Care (Panel Discussion). Association of Community Cancer Centers, ACCC 35th National Oncology Conference, Phoenix, USA, October 2018
- **Alkhatib N.** Introduction to Health Economics in USA, and Countries of Gulf Cooperation Council (GCC). Center for Health Outcomes and PharmacoEconomic Research (HOPE). Summer post-doc training, University of Arizona, Tucson, USA, Summer 2018
- **Alkhatib N.** Future of International Pharmaceutical Students' Federation (IPSF) in Eastern Mediterranean Region. Regional IPSF Symposium, University of Qatar, Doha, Qatar, June 2011

14. Invited Interviews

- **Alkhatib N.** Integrating Biosimilars Within a Community, Academic, or Health-System Setting. 2019: <https://www.accc-cancer.org/home/learn/immunotherapy/resource-detail/integrating-biosimilars-within-a-community-academic-or-health-system-setting>
- **Alkhatib N, McBride A, Earl M, Patel K.** Expert Panel Discusses the Financial and Economic Impact of Biosimilars Targeted Oncology 2018. <https://www.targetedonc.com/conference/accc-noc-2018/expert-panel-discusses-the-financial-and-economic-impact-of-biosimilars>
- **Alsaid N.** Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia. AJMC Managed Markets Network 2018. <https://www.ajmc.com/conferences/ash-2017/ibrutinib-more-effective-than-stemcell-transplant-in-patients-with-form-of-chronic-leukemia>

15. Organizational Services

- Research Group Leader for Arizona Health Department Funded Project, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2017-present).
- Hematology and Oncology Research Group Leader, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2016-present).
- Post-Doc Trainer, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2016- present).



- Social Chair, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), University of Arizona Chapter (2016-2017).
- Regional Project Officer, International Pharmaceutical Students' Federation (IPSF), Eastern Mediterranean Region (2010-2011)
- Member, Jordanian Pharmaceutical Association. Jordan (2011-present).

16. Publications

Peer Reviewed Articles

Submitted

1. **Alkhatib N**, McBride A, Oh M, Persky D, Anwer F, Andritsos L, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Venetoclax versus Ibrutinib versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. Target journal: JAMA Oncology
2. Alrawashdh N, **Alkhatib N**, McBride A, Persky D, Abraham I. Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. Target Journal: Journal of Medical Economics
3. **Alkhatib N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Economic Evaluation of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). Target journal: Journal of the American Medical Association
4. Turner M, **Alkhatib N**, MacDonald K, Ludwig H, Apro M, Gascón P, Abraham I. Erythropoiesis-Stimulating Agents and Mortality in Cancer Patients with Chemotherapy-Induced Anemia: Meta-Analysis
5. Abraham I, **Alkhatib N**, Gascón P, Apro M, Ludwig H, Lee CS, Martin J, Logue M, Kutob R, Nuño T, Olvey E, Harrington A, MacDonald K. Erythropoiesis-Stimulating Agents and Survival/Mortality in Cancer Patients with Anemia: Systematic Review of Meta-Analyses Seven Pooled Analyses Published since 2005

Published

Articles 8 to 15 as a special issue in the Journal of Medical Economics

6. **Alkhatib N**, Abraham I. The Six Delta Platform for Outcome-Based Contracting for Pharmaceuticals *Journal of Medical Economics* 2020.
7. **Alkhatib N**, Ramos K, Erstad B, Slack M, McBride A, Bhattacharjee S, Abraham I. Pricing Methods in Outcome-Based Contracting: δ 1: Cost Effectiveness Analysis and Cost-Utility Analysis-Based Pricing. *Journal of Medical Economics* 2020.
8. **Alkhatib N**, Ramos K, Erstad B, Slack M, McBride A, Bhattacharjee S, Abraham I. Pricing Methods in Outcome-Based Contracting: δ 2: Willingness-To-Pay-Based Pricing. *Journal of Medical Economics* 2020.
9. **Alkhatib N**, Erstad B, Ramos K, McBride A, Bhattacharjee S, Slack M, Abraham I. Pricing Methods: δ 3: Reference-Based Pricing. *Journal of Medical Economics* 2020.
10. **Alkhatib N**, Bhattacharjee S, McBride A, Ramos K, Slack M, Erstad B, Abraham I. Pricing Methods in Outcome-Based Contracting: δ 4: Safety-Based Pricing. *Journal of Medical Economics* 2020.
11. **Alkhatib N**, McBride A, Bhattacharjee S, Ramos K, Erstad B, Slack M, Billheimer D, Abraham I. Pricing Methods in Outcome-Based Contracting: δ 5: Risk of Efficacy Failure-Based Pricing. *Journal of Medical Economics* 2020.
12. **Alkhatib N**, Slack M, Bhattacharjee S, Erstad B, Ramos K, McBride A, Abraham I. Pricing Methods in Outcome-Based Contracting: δ 6: Adherence-Based Pricing. *Journal of Medical Economics* 2020.

13. **Alkhatib N**, McBride A, Slack M, Bhattacharjee S, Erstad B, Ramos K, Abraham I. Pricing Methods in Outcome-Based Contracting: Integration Analysis of the Six Dimensions (6 δ 's). *Journal of Medical Economics* 2020.
14. **Alkhatib N**, Sweitzer N, Erstad B, Slack M, Gharaibeh M, Karnes J, Larriva M, Klimecki W, Ramos N, Abraham I. Ex Ante Economic Evaluation of Bucindolol vs. Carvedilol with and without Arg389 Beta1-Adrenergic Receptor Polymorphism Testing in Stage III/IV Heart Failure. *American Journal of Cardiovascular Drugs* 2020.
15. Hacene M, Saker M, Youcef A, Koudri S, Cheriet S, Mercouk H, Lounici A, **Alkhatib N**. Insulin injection technique in Western region of Algeria, Tlemcen. *Pan African Medical Journal* 2020
16. Oh M, Patanwala A, **Alkhatib N**, Almutairi A, Abraham I, Erstad B. Cost Benefit Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: US Payer Perspective. *Critical Care Medicine* 2020.
17. Andritsos L, McBride A, Huff K, Huang Y, Fan T, **Alkhatib N**, Abraham I, Drea E. Clinical and Cost Outcomes of Pre-Emptive Plerixafor Administration in Patients with Multiple Myeloma Undergoing Stem Cell Mobilization. *Leukemia Research* 2019.
18. Alfayez O, AlYami M, Alshibani M, Fallataha S, Alkhusaym N, Alsheikh R, **Alkhatib N**. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. *Primary Care Diabetes* 2019.
19. Almutairi A, Alkhatib N, Abraham I. The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs—Reply. *JAMA Dermatology* 2018.
20. Almutairi A, **Alkhatib N**, Oh M, Lewandrowski C, Babiker H, Cranmer L, McBride A, Abraham I. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients with Advanced Unresectable Melanoma. *JAMA Dermatology* 2018.
21. **Alkhatib N**, Ramos N, Sweitzer N, Slack M, Erstad B, Gharaibeh M, Klimecki W, Larriva M, Karnes J, Abraham I. Ex Ante Economic Evaluation of Genetic Testing for the Arg-389 Beta1-Adrenergic Receptor Polymorphism to Support Bucindolol Treatment Decisions in Stage III/IV Heart Failure. *Expert Review of Precision Medicine and Drug Development* 2018.
22. Kelley E, Snyder E, **Alkhatib N**, Snyder S, Sprissler R, Olson T, Akre M, Abraham I. Economic Evaluation of a Pharmacogenomic Multi-Gene Panel Test to Optimize Anti-Hypertension Therapy: Simulation Study. *Journal of Medical Economics* 2018.
23. Gharaibeh M, McBride A, Alberts D, Slack M, Erstad B, **Alsaid N**, Bootman J, Abraham I. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. *Pharmacoeconomics* 2018.
24. Gharaibeh M, McBride A, Alberts D, Slack M, Erstad B, **Alsaid N**, Bootman J, Abraham I. Economic Evaluation for UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. *Pharmacoeconomics* 2018.
25. Zhou L, Almutairi L, **Alsaid N**, Warholak T, Cooley J. Establishing the Validity and Reliability Evidence of Preceptor Assessment of Student Tool Designed to Assess Rotation Performance of Doctor of Pharmacy Students: A Rasch Analysis. *American Journal of Pharmaceutical Education (AJPE)* 2016.

Abstracts Accepted

1. **Alkhatib N**, Choi B, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS). American Society of Clinical Oncology (ASCO) 2019 USA.



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

2. Choi B, **Alkhatib N**, Pae E, Babiker H, Garland L, Henglefeld A, McBride A, Abraham I. Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) 2019 USA.
3. Alrawashdh N, **Alkhatib N**, McBride A, Persky D, Abraham I. Economic Evaluation for the US of Ibrutinib versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. American Society of Hematology (ASH) 2018 USA
4. **Alsaid N**, McBride A, Abraham I. Economic Evaluation for the US of Ibrutinib versus Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Clinical Oncology (ASCO) 2018 USA
5. Oh M, Almutairi A, **Alsaid N**, Babiker H, McBride A, Abraham I. Progression-Free(PFS) and Overall Survival (OS) in Treatment of BRAF Mutation-Positive Metastatic Melanoma: Bayesian Network Meta-Analysis. American Society of Clinical Oncology (ASCO)2018 USA
6. **Alsaid N**, McBride A, Oh M, Persky D, Anwer F, Andritsos L, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
7. **Alsaid N**, McBride A, Kim H, Oh M, Andritsos L, Anwar F, Persky D, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Ibrutinib versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
8. **Alsaid N**, Sweitzer N, Ramos N, Abraham I. Systematic Review for Causes of Hospitalization in Cost-Effectiveness Studies. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Europe
9. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Economic Evaluation of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). World Congress of Pharmacy and Pharmaceutical Sciences (FIP) 2017 South Korea
10. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Cost-Effectiveness of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). American Society of Clinical Oncology (ASCO) 2017 USA
11. **Alsaid N**, McBride A, Abraham I. Cost-effectiveness of Daratumumab 10mg+Dacarbazine versus Dacarbazine Alone in Metastatic/Advanced Melanoma. Western Pharmacoeconomics Conference 2017 USA
12. **Alsaid N**, Almutairi A, Fazel M, Lee J, Slack M. Information Required in Research Reports for Inclusion in Meta- analysis: Cohort Studies for Evaluating the Impact of Pharmacist Care on Diabetes Outcomes. American Society of Health-System Pharmacists (ASHP) midyear scientific sessions 2016 USA



QFG11/0110 - 3.1E	Curriculum Vitae Form - Procedures of Appointment and Promotion Committee
-------------------	---